Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Accenture
Daiichi Sankyo
Cerilliant
Federal Trade Commission
US Department of Justice
Boehringer Ingelheim
UBS
US Army

Generated: October 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 011522

« Back to Dashboard
NDA 011522 describes ADDERALL 7.5, which is a drug marketed by Teva Womens and is included in one NDA. There is one patent protecting this drug. Additional details are available on the ADDERALL 7.5 profile page.

The generic ingredient in ADDERALL 7.5 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-three drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Summary for NDA: 011522

Tradename:
7
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Summary for product number 007

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength2.5MG;2.5MG;2.5MG;2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 13, 1996TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jan 6, 2021Product Flag?Substance Flag?Delist Request?Y

Summary for product number 008

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength5MG;5MG;5MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Feb 13, 1996TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jan 6, 2021Product Flag?Substance Flag?Delist Request?Y

Summary for product number 009

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength1.25MG;1.25MG;1.25MG;1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:May 12, 1997TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jan 6, 2021Product Flag?Substance Flag?Delist Request?Y


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Medtronic
Dow
US Department of Justice
Cantor Fitzgerald
Queensland Health
Julphar
Mallinckrodt
Fish and Richardson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot